Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C

A Phase 2 Study of VX-950 in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects With Hepatitis C

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00262483

Enrollment

Registered

2005-12-06

Start date

2005-12-31

Completion date

2006-04-30

Last updated

2007-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis C

Brief summary

To assess the safety of the combination of VX-950, Pegasys and Copegus in subjects with hepatitis C.

Interventions

DRUGVX-950

DRUGribavirin

DRUGpeginterferon alfa-2a

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Infected with hepatitis C virus

Exclusion criteria

* Contraindications to peginterferon or ribavirin therapy.

Design outcomes

Primary

Measure	Time frame
Safety of triple combination therapy.	retrospective and prospective

Secondary

Measure	Time frame
Pharmacokinetics of VX-950, peginterferon alfa-2a and ribavirin.	retrospective and prospective
Plasma HCV RNA levels	retrospective and prospective

Countries

Puerto Rico, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026